Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

Lancet Oncol. 2005 Sep;6(9):724-7. doi: 10.1016/S1470-2045(05)70321-1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Benzamides
  • Diagnostic Errors / prevention & control
  • Drug Monitoring / methods
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / genetics
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / secondary
  • Glucose-6-Phosphate / analogs & derivatives
  • Humans
  • Imatinib Mesylate
  • Middle Aged
  • Piperazines / pharmacology*
  • Positron-Emission Tomography
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyrimidines / pharmacology*
  • Sequence Deletion*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • 2-fluoro-2-deoxyglucose-6-phosphate
  • Glucose-6-Phosphate
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit